The Chemotherapy Induced Neutropenia drugs in development market research report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chemotherapy Induced Neutropenia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued products.

GlobalData tracks 35 drugs in development for Chemotherapy Induced Neutropenia by 31 companies/universities/institutes. The top development phase for Chemotherapy Induced Neutropenia is preclinical with nine drugs in that stage. The Chemotherapy Induced Neutropenia pipeline has 34 drugs in development by companies and one by universities/ institutes. Some of the companies in the Chemotherapy Induced Neutropenia pipeline products market are: Biogenomics, Bolder Biotechnology and Lupin.

The key targets in the Chemotherapy Induced Neutropenia pipeline products market include Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R), Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA), and Interleukin 1 Receptor (IL1R).

The key mechanisms of action in the Chemotherapy Induced Neutropenia pipeline product include Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) Agonist with 27 drugs in Pre-Registration. The Chemotherapy Induced Neutropenia pipeline products include five routes of administration with the top ROA being Subcutaneous and four key molecule types in the Chemotherapy Induced Neutropenia pipeline products market including Recombinant Protein, and Small Molecule.

Chemotherapy Induced Neutropenia overview

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain, dizziness, and abdominal pain. The predisposing factors include age, co-morbidities, and time course of therapy.

For a complete picture of Chemotherapy Induced Neutropenia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.